Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study.
Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study. Am J Ther. 2018 Nov/Dec; 25(6):e767-e768.
View in:
PubMed
subject areas
Aged
Aged
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Carcinoma, Non-Small-Cell Lung
Carcinoma, Non-Small-Cell Lung
Cost-Benefit Analysis
Cost-Benefit Analysis
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Female
Female
Humans
Humans
Kaplan-Meier Estimate
Kaplan-Meier Estimate
Lung Neoplasms
Lung Neoplasms
Male
Male
Middle Aged
Middle Aged
authors with profiles
Raid Aljumaily
Sami Ibrahimi
Sara Vesely